| First Author | Zalevsky J | Year | 2010 |
| Journal | Nat Biotechnol | Volume | 28 |
| Issue | 2 | Pages | 157-9 |
| PubMed ID | 20081867 | Mgi Jnum | J:161273 |
| Mgi Id | MGI:4457921 | Doi | 10.1038/nbt.1601 |
| Citation | Zalevsky J, et al. (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28(2):157-9 |
| abstractText | Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life in vivo. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1(-/-) mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy. |
